{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T12:31:41Z","timestamp":1780835501149,"version":"3.54.1"},"reference-count":250,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Ministry of Education, Youth and Sports of the Czech Republic","award":["LTAUSA17061"],"award-info":[{"award-number":["LTAUSA17061"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Several strategies have been developed to fight viral infections, not only in humans but also in animals and plants. Some of them are based on the development of efficient vaccines, to target the virus by developed antibodies, others focus on finding antiviral compounds with activities that inhibit selected virus replication steps. Currently, there is an increasing number of antiviral drugs on the market; however, some have unpleasant side effects, are toxic to cells, or the viruses quickly develop resistance to them. As the current situation shows, the combination of multiple antiviral strategies or the combination of the use of various compounds within one strategy is very important. The most desirable are combinations of drugs that inhibit different steps in the virus life cycle. This is an important issue especially for RNA viruses, which replicate their genomes using error-prone RNA polymerases and rapidly develop mutants resistant to applied antiviral compounds. Here, we focus on compounds targeting viral structural capsid proteins, thereby inhibiting virus assembly or disassembly, virus binding to cellular receptors, or acting by inhibiting other virus replication mechanisms. This review is an update of existing papers on a similar topic, by focusing on the most recent advances in the rapidly evolving research of compounds targeting capsid proteins of RNA viruses.<\/jats:p>","DOI":"10.3390\/v14020174","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T22:47:32Z","timestamp":1642546052000},"page":"174","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting the Virus Capsid as a Tool to Fight RNA Viruses"],"prefix":"10.3390","volume":"14","author":[{"given":"Lucie","family":"Hoz\u00e1kov\u00e1","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technick\u00e1 3, 166 28 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"Vokat\u00e1","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technick\u00e1 3, 166 28 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5698-4366","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Ruml","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technick\u00e1 3, 166 28 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-8210","authenticated-orcid":false,"given":"Pavel","family":"Ulbrich","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technick\u00e1 3, 166 28 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13910","DOI":"10.1073\/pnas.96.24.13910","article-title":"Mutation rates among RNA viruses","volume":"96","author":"Drake","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.virusres.2004.11.004","article-title":"Incorporation fidelity of the viral RNA-dependent RNA polymerase: A kinetic, thermodynamic and structural perspective","volume":"107","author":"Castro","year":"2005","journal-title":"Virus Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s12033-010-9251-z","article-title":"Cell-based assays for high-throughput screening","volume":"45","author":"An","year":"2010","journal-title":"Mol. Biotechnol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.biotechadv.2017.12.016","article-title":"In vitro methods for testing antiviral drugs","volume":"36","author":"Ruml","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd1086","article-title":"Hit and lead generation: Beyond high-throughput screening","volume":"2","author":"Bleicher","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1359-6446(00)01468-9","article-title":"Chemical ligands, genomics and drug discovery","volume":"5","author":"Lenz","year":"2000","journal-title":"Drug Discov. Today"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature11169","article-title":"Structure of the immature retroviral capsid at 8\u2009\u00c5 resolution by cryo-electron microscopy","volume":"487","author":"Bharat","year":"2012","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature13838","article-title":"Structure of the immature HIV-1 capsid in intact virus particles at 8.8 A resolution","volume":"517","author":"Schur","year":"2015","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrmicro3490","article-title":"HIV-1 assembly, release and maturation","volume":"13","author":"Freed","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virol.2015.08.029","article-title":"FAITH\u2014Fast assembly inhibitor test for HIV","volume":"486","author":"Ruml","year":"2015","journal-title":"Virology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17076","DOI":"10.1038\/s41598-019-53483-w","article-title":"A simple, high-throughput stabilization assay to test HIV-1 uncoating inhibitors","volume":"9","author":"Kaufman","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhang, X., Jia, R., Zhou, J., Wang, M., Yin, Z., and Cheng, A. (2016). Capsid-targeted viral inactivation: A novel tactic for inhibiting replication in viral infections. Viruses, 8.","DOI":"10.3390\/v8090258"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1073\/pnas.92.2.364","article-title":"Targeting of a nuclease to murine leukemia virus capsids inhibits viral multiplication","volume":"92","author":"Natsoulis","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.1074\/jbc.M006335200","article-title":"Significant interference with Hepatitis B virus replication by a Core-nuclease fusion protein","volume":"276","author":"Beterams","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00705-005-0631-9","article-title":"Capsid-targeted viral inactivation can destroy dengue 2 virus from within in vitro","volume":"151","author":"Qin","year":"2006","journal-title":"Arch. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/10430340050015725","article-title":"Packageable antiviral therapeutics against human immunodeficiency virus type 1: Virion-targeted virus inactivation by incorporation of a single-chain antibody against viral integrase into progeny virions","volume":"11","author":"Okui","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1128\/JVI.72.7.5441-5448.1998","article-title":"Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins","volume":"72","author":"Kobinger","year":"1998","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1128\/jvi.70.7.4329-4337.1996","article-title":"Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures","volume":"70","author":"Schumann","year":"1996","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/352632a0","article-title":"New antiviral strategy using capsid-nuclease fusion proteins","volume":"352","author":"Natsoulis","year":"1991","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.gt.3300421","article-title":"Antiretroviral effect of a gag-RNase HI fusion gene","volume":"4","author":"Schumann","year":"1997","journal-title":"Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1107\/S1744309106055461","article-title":"Crystallization and preliminary X-ray analysis of Escherichia coli RNase HI-dsRNA complexes","volume":"63","author":"Loukachevitch","year":"2007","journal-title":"Acta Crystallogr. Sect. F Struct Biol. Cryst. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1128\/jvi.71.4.3312-3318.1997","article-title":"Expression of a murine leukemia virus Gag-Escherichia coli RNase HI fusion polyprotein significantly inhibits virus spread","volume":"71","author":"VanBrocklin","year":"1997","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm.3626","article-title":"The ribonuclease activity of SAMHD1 is required for HIV-1 restriction","volume":"20","author":"Ryoo","year":"2014","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and Influenza","volume":"181","author":"Abbott","year":"2020","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.bbrc.2008.04.121","article-title":"Adenoviral-vector mediated transfer of HBV-targeted ribonuclease can inhibit HBV replication in vivo","volume":"371","author":"Zhao","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_26","first-page":"1956","article-title":"Construction of transgenic P0 grass carp by capsid-targeted viral inactivation of reovirus","volume":"38","author":"Qin","year":"2014","journal-title":"J. Fisher China"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1742-4690-9-17","article-title":"Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein","volume":"9","author":"Nangola","year":"2012","journal-title":"Retrovirology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10822-014-9772-9","article-title":"Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex","volume":"28","author":"Praditwongwan","year":"2014","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nsmb964","article-title":"A peptide inhibitor of HIV-1 assembly in vitro","volume":"12","author":"Sticht","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nsmb967","article-title":"The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor","volume":"12","author":"Ternois","year":"2005","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"P108","DOI":"10.1186\/1742-4690-10-S1-P108","article-title":"Thermodynamic characterization of the peptide assembly inhibitor binding to HIV-1 capsid protein","volume":"10","author":"Kozisek","year":"2013","journal-title":"Retrovirology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jmb.2008.02.066","article-title":"A cell-penetrating helical peptide as a potential HIV-1 inhibitor","volume":"378","author":"Zhang","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16274","DOI":"10.1074\/jbc.C800048200","article-title":"Solution structure of a hydrocarbon stapled peptide inhibitor in complex with monomeric C-terminal domain of HIV-1 capsid","volume":"283","author":"Bhattacharya","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1742-4690-10-136","article-title":"Dual-acting stapled peptides target both HIV-1 entry and assembly","volume":"10","author":"Zhang","year":"2013","journal-title":"Retrovirology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1110\/ps.03555304","article-title":"The dimerization domain of the HIV-1 capsid protein binds a capsid protein-derived peptide: A biophysical characterization","volume":"13","author":"Barrera","year":"2004","journal-title":"Protein Sci."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bocanegra, R., Nevot, M., Dom\u00e9nech, R., L\u00f3pez, I., Abi\u00e1n, O., Rodr\u00edguez-Huete, A., Cavasotto, C.N., Vel\u00e1zquez-Campoy, A., G\u00f3mez, J., and Mart\u00ednez, M. (2011). Rationally designed interfacial peptides are efficient in vitro inhibitors of HIV-1 capsid assembly with antiviral activity. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023877"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cell.2009.04.063","article-title":"X-ray structures of the hexameric building block of the HIV capsid","volume":"137","author":"Pornillos","year":"2009","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1742-4690-8-28","article-title":"Antiviral activity of \u03b1-helical stapled peptides designed from the HIV-1 capsid dimerization domain","volume":"8","author":"Zhang","year":"2011","journal-title":"Retrovirology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0022-2836(03)00289-4","article-title":"Antiviral inhibition of the HIV-1 capsid protein","volume":"327","author":"Tang","year":"2003","journal-title":"J. Mol. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jmb.2007.07.070","article-title":"Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein","volume":"373","author":"Kelly","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_41","unstructured":"Prevelige, P. (2009). Small molecule inhibitors of HIV-1 capsid assembly. (Application No. 12\/090,361), U.S. Patent."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.bmcl.2009.02.116","article-title":"Synthesis and antiviral activities of novel acylhydrazone derivatives targeting HIV-1 capsid protein","volume":"19","author":"Tian","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1128\/JVI.01406-10","article-title":"Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization","volume":"85","author":"Shi","year":"2011","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2007.09.028","article-title":"How to assemble a capsid","volume":"131","author":"Sundquist","year":"2007","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1128\/JVI.00493-12","article-title":"Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein","volume":"86","author":"Lemke","year":"2012","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bmcl.2010.10.131","article-title":"Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly","volume":"21","author":"Fader","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/cb400075f","article-title":"Novel inhibitor binding site discovery on HIV-1 capsid N-terminal domain by NMR and X-ray crystallography","volume":"8","author":"Goudreau","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1128\/AAC.00299-11","article-title":"Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system","volume":"55","author":"Urano","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bmcl.2015.11.036","article-title":"Synthesis of the biotinylated anti-HIV compound BMMP and the target identification study","volume":"26","author":"Kamo","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Blair, W.S., Pickford, C., Irving, S.L., Brown, D.G., Anderson, M., Bazin, R., Cao, J., Ciaramella, G., Isaacson, J., and Jackson, L. (2010). HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001220"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1128\/JVI.01705-13","article-title":"Human cytosolic extracts stabilize the HIV-1 core","volume":"87","author":"Fricke","year":"2013","journal-title":"J Virol"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18625","DOI":"10.1073\/pnas.1419945112","article-title":"Structural basis of HIV-1 capsid recognition by PF74 and CPSF6","volume":"111","author":"Bhattacharya","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1128\/JVI.03116-15","article-title":"Roles of capsid-interacting host factors in multimodal inhibition of HIV-1 by PF74","volume":"90","author":"Saito","year":"2016","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-019-0560-x","article-title":"A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model","volume":"25","author":"Yant","year":"2019","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3389\/fmicb.2019.01227","article-title":"GS-CA compounds: First-in-class HIV-1 capsid inhibitors covering multiple grounds","volume":"10","author":"Singh","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1128\/jvi.66.8.4874-4883.1992","article-title":"Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro","volume":"66","author":"Ehrlich","year":"1992","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1128\/JVI.78.5.2545-2552.2004","article-title":"Assembly properties of the human immunodeficiency virus type 1 CA protein","volume":"78","author":"Stray","year":"2004","journal-title":"J. Virol."},{"key":"ref_58","unstructured":"Tse, W.C., Link, J.O., Mulato, A., Niedziela-Majka, A., Rowe, W., Somoza, J.R., Villasenor, A.G., Yant, S.R., Zhang, J.R., and Zheng, J. (2017, January 13\u201316). Discovery of Novel Potent HIV Capsid Inhibitors with Long-Acting Potential. Proceedings of the CROI, Seattle, WA, USA."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1093\/ofid\/ofy210.548","article-title":"539. GS-CA2: A novel, potent, and selective first-in-class inhibitor of HIV-1 capsid function displays nonclinical pharmacokinetics supporting long-acting potential in humans","volume":"Volume 5","author":"Zheng","year":"2018","journal-title":"Open Forum Infectious Diseases"},{"key":"ref_60","unstructured":"Jennifer, E., Sager, R.B., Martin, R., Steve, K.W., John, L., Scott, D.S., Winston, C.T., and Anita, M. (2019, January 4\u20137). Safety and PK of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor. Proceedings of the CROI, Seattle, WA, USA."},{"key":"ref_61","unstructured":"Daar, E.S., McDonald, C., Crofoot, G., Ruane, P., Sinclair, G., Patel, H., Begley, R., Liu, Y.P., Brainard, D.M., and Hyland, R.H. (2019, January 6\u20139). Single doses of long-acting capsid inhibitor GS-6207 administered by subcutaneous injection are safe and efficacious in people living with HIV. Proceedings of the 17th European AIDS Conference, Basel, Switzerland."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.cell.2021.01.025","article-title":"Cone-shaped HIV-1 capsids are transported through intact nuclear pores","volume":"184","author":"Zila","year":"2021","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1128\/AAC.00985-13","article-title":"Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes","volume":"57","author":"Lamorte","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12977-014-0120-x","article-title":"BI-2 destabilizes HIV-1 cores during infection and prevents binding of CPSF6 to the HIV-1 capsid","volume":"11","author":"Fricke","year":"2014","journal-title":"Retrovirology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.283.5398.80","article-title":"Assembly and analysis of conical models for the HIV-1 core","volume":"283","author":"Ganser","year":"1999","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jmb.2011.04.021","article-title":"The molecular architecture of HIV","volume":"410","author":"Briggs","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Price, A.J., Fletcher, A.J., Schaller, T., Elliott, T., Lee, K., KewalRamani, V.N., Chin, J.W., Towers, G.J., and James, L.C. (2012). CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog., 8.","DOI":"10.2210\/pdb4b4n\/pdb"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1021\/acs.jmedchem.0c00015","article-title":"Design, synthesis, and mechanism study of benzenesulfonamide-containing phenylalanine derivatives as novel HIV-1 capsid inhibitors with improved antiviral activities","volume":"63","author":"Sun","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"113848","DOI":"10.1016\/j.ejmech.2021.113848","article-title":"Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors","volume":"226","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10822-006-9077-8","article-title":"Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors","volume":"20","author":"Kortagere","year":"2006","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8472","DOI":"10.1128\/JVI.05006-11","article-title":"Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid","volume":"86","author":"Kortagere","year":"2012","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/acs.biochem.1c00228","article-title":"Identification of a potential inhibitor of the FIV p24 capsid protein and characterization of its binding site","volume":"60","author":"Long","year":"2021","journal-title":"Biochemistry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC\u2014A free database of commercially available compounds for virtual screening","volume":"45","author":"Irwin","year":"2005","journal-title":"J. Chem. Inf. Model"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bmc.2010.11.045","article-title":"Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid","volume":"19","author":"Curreli","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1128\/AAC.02574-15","article-title":"Ebselen, a small-molecule capsid inhibitor of HIV-1 replication","volume":"60","author":"Brady","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/tx0601105","article-title":"Ebselen, a seleno-organic antioxidant, as an electrophile","volume":"19","author":"Sakurai","year":"2006","journal-title":"Chem. Res. Toxicol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1021\/acschembio.5b00347","article-title":"Targeting the early step of building block organization in viral capsid assembly","volume":"10","author":"Lampel","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"104544","DOI":"10.1016\/j.antiviral.2019.104544","article-title":"A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-terminal domain of capsid","volume":"169","author":"Zhang","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1021\/np50104a008","article-title":"Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids","volume":"57","author":"Fujioka","year":"1994","journal-title":"J. Nat. Prod."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1128\/JVI.01926-10","article-title":"HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice","volume":"85","author":"Keller","year":"2011","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1742-4690-8-101","article-title":"The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles","volume":"8","author":"Nguyen","year":"2011","journal-title":"Retrovirology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"13555","DOI":"10.1073\/pnas.2234683100","article-title":"PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing","volume":"100","author":"Li","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/bdd.625","article-title":"The absorption, distribution, metabolism and elimination of bevirimat in rats","volume":"29","author":"Bullock","year":"2008","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1128\/AAC.00152-07","article-title":"Phase I and II study of the safety, virologic effect, and pharmacokinetics\/pharmacodynamics of single-dose 3-o-(3\u2032,3\u2032-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection","volume":"51","author":"Smith","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.01650-08","article-title":"Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1","volume":"53","author":"Salzwedel","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.01784-09","article-title":"Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat","volume":"54","author":"Margot","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.01868-10","article-title":"In vitro selection of clinically relevant bevirimat resistance mutations revealed by \u201cdeep\u201d sequencing of serially passaged, quasispecies-containing recombinant HIV-1","volume":"49","author":"Knapp","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Reed, J.C., Solas, D., Kitaygorodskyy, A., Freeman, B., Ressler, D.T.B., Phuong, D.J., Swain, J.V., Matlack, K., Hurt, C.R., and Lingappa, V.R. (2021). Identification of an antiretroviral small molecule that appears to be a host-targeting inhibitor of HIV-1 assembly. J. Virol., 95.","DOI":"10.1128\/JVI.00883-20"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Teow, S.Y., Mualif, S.A., Omar, T.C., Wei, C.Y., Yusoff, N.M., and Ali, S.A. (2013). Production and purification of polymerization-competent HIV-1 capsid protein p24 (CA) in NiCo21(DE3) Escherichia coli. BMC Biotechnol., 13.","DOI":"10.1186\/1472-6750-13-107"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ali, S.A., Teow, S.Y., Omar, T.C., Khoo, A.S., Choon, T.S., and Yusoff, N.M. (2016). A cell internalizing antibody targeting capsid protein (p24) inhibits the replication of HIV-1 in T cells lines and PBMCs: A proof of concept study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0145986"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/biom2020187","article-title":"Cell penetrating peptides in the delivery of biopharmaceuticals","volume":"2","author":"Munyendo","year":"2012","journal-title":"Biomolecules"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-1759(01)00410-0","article-title":"Chemical engineering of cell penetrating antibodies","volume":"254","author":"Zhao","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0968-0896(97)00158-2","article-title":"Anti-AIDS agents\u2014XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives","volume":"5","author":"Hashimoto","year":"1997","journal-title":"Bioorg. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Prifti, G.M., Moianos, D., Giannakopoulou, E., Pardali, V., Tavis, J.E., and Zoidis, G. (2021). Recent advances in hepatitis B treatment. Pharmaceuticals, 14.","DOI":"10.3390\/ph14050417"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.3748\/wjg.v27.i21.2727","article-title":"Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure","volume":"27","author":"Tsounis","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"104925","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/386091a0","article-title":"Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy","volume":"386","author":"Conway","year":"1997","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1128\/JVI.02033-09","article-title":"Conformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assembly","volume":"84","author":"Packianathan","year":"2010","journal-title":"J. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41598-017-01568-9","article-title":"Allosteric conformational changes of human HBV core protein transform its assembly","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cbpa.2019.02.009","article-title":"Recent advances in the development of HBV capsid assembly modulators","volume":"50","author":"Nijampatnam","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(70)90926-8","article-title":"Virus-like particles in serum of patients with Australia-antigen associated hepatitis","volume":"295","author":"Dane","year":"1970","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"104917","DOI":"10.1016\/j.antiviral.2020.104917","article-title":"Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B","volume":"182","author":"Viswanathan","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1021\/acsinfecdis.8b00337","article-title":"Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: Recent advances and perspectives","volume":"5","author":"Yang","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-981-16-0267-2_5","article-title":"Moving fast toward hepatitis B virus elimination","volume":"1322","author":"Bassit","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jmr.801","article-title":"BAY 41-4109 has multiple effects on hepatitis B virus capsid assembly","volume":"19","author":"Stray","year":"2006","journal-title":"J. Mol. Recognit."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0409732102","article-title":"A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly","volume":"102","author":"Stray","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.coph.2016.08.004","article-title":"Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection","volume":"30","author":"Cole","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1128\/JVI.00582-13","article-title":"Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids","volume":"87","author":"Campagna","year":"2013","journal-title":"J. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1021\/acs.jmedchem.7b00083","article-title":"Discovery and pre-clinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors","volume":"60","author":"Qiu","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/acsinfecdis.8b00269","article-title":"Discovery of novel hepatitis B virus nucleocapsid assembly inhibitors","volume":"5","author":"Zhang","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.antiviral.2011.08.012","article-title":"The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication","volume":"92","author":"Billioud","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hep.30514","article-title":"Direct inhibition of hepatitis B e antigen by core protein allosteric modulator","volume":"70","author":"Yan","year":"2019","journal-title":"Hepatology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Feld","year":"2007","journal-title":"Antivir. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"42374","DOI":"10.1038\/srep42374","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2017.10.017","article-title":"Efficacy of NVR 3-778, alone and in combination with pegylated interferon, vs. Entecavir in uPA\/SCID mice with humanized livers and HBV infection","volume":"154","author":"Klumpp","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_118","unstructured":"Aktoudianakis, E.R.C., Canales, E., Currie, K.S., Kato, D., Li, J., Link, J.O., Metobo, S.E., Saito, R.D., Schroeder, S.D., and Shapiro, N. (2017). Compounds for the Treatment of Hepatitis B Virus Infections. (Application No. 20180251460), U.S. Patent."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(18)30422-7","article-title":"LBO-003-RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated","volume":"68","author":"Gane","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Feng, S., Gane, E., Schwabe, C., Zhu, M., Triyatni, M., Zhou, J., Bo, Q., and Jin, Y. (2020). A five-in-one first-in-human study to assess safety, tolerability, and pharmacokinetics of RO7049389, an inhibitor of hepatitis B virus capsid assembly, after single and multiple ascending doses in healthy participants. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01323-20"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1021\/acsmedchemlett.9b00550","article-title":"Discovery of a new sulfonamide hepatitis B capsid assembly modulator","volume":"11","author":"Na","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1021\/acsmedchemlett.0c00606","article-title":"Sulfamoylbenzamide-based capsid assembly modulators for selective inhibition of hepatitis B viral replication","volume":"12","author":"Lee","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejmech.2017.06.062","article-title":"Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector","volume":"138","author":"Sari","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Hurwitz, S.J., McBrearty, N., Arzumanyan, A., Bichenkov, E., Tao, S., Bassit, L., Chen, Z., Kohler, J.J., Amblard, F., and Feitelson, M.A. (2021). Studies on the efficacy, potential cardiotoxicity and monkey pharmacokinetics of GLP-26 as a potent hepatitis B virus capsid assembly modulator. Viruses, 13.","DOI":"10.3390\/v13010114"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e01701-19","DOI":"10.1128\/AAC.01701-19","article-title":"Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses in vitro and in humanized mice","volume":"64","author":"Amblard","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejmech.2019.01.059","article-title":"Design and synthesis of aminothiazole based hepatitis B virus (HBV) capsid inhibitors","volume":"166","author":"Pan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.bioorg.2019.103363","article-title":"Design, synthesis and anti-HBV activity of NVR3-778 derivatives","volume":"94","author":"Lv","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2018.12.029","article-title":"Molecular mechanisms of tetrahydropyrrolo[1,2-c]pyrimidines as HBV capsid assembly inhibitors","volume":"663","author":"Song","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1021\/acs.jmedchem.8b00654","article-title":"Synthesis and evaluation of N-phenyl-3-sulfamoyl-benzamide derivatives as capsid assembly modulators inhibiting hepatitis B virus (HBV)","volume":"61","author":"Vandyck","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2016.11.026","article-title":"Exploring the binding mechanism of heteroaryldihydropyrimidines and hepatitis B virus capsid combined 3D-QSAR and molecular dynamics","volume":"137","author":"Tu","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00044-020-02677-3","article-title":"Synthesis of 4-oxotetrahydropyrimidine-1(2H)-carboxamides derivatives as capsid assembly modulators of hepatitis B virus","volume":"30","author":"Hwang","year":"2021","journal-title":"Med. Chem. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"112495","DOI":"10.1016\/j.ejmech.2020.112495","article-title":"Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors","volume":"202","author":"Jia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/aps.2013.175","article-title":"Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation","volume":"35","author":"Yang","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejmech.2016.07.048","article-title":"Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors","volume":"123","author":"Jia","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"197677","DOI":"10.1016\/j.virusres.2019.197677","article-title":"Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly","volume":"271","author":"Toyama","year":"2019","journal-title":"Virus Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"127848","DOI":"10.1016\/j.bmcl.2021.127848","article-title":"Identification of a new class of HBV capsid assembly modulator","volume":"39","author":"Kuduk","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"116096","DOI":"10.1016\/j.bmc.2021.116096","article-title":"Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays","volume":"36","author":"Wang","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"198565","DOI":"10.1016\/j.virusres.2021.198565","article-title":"Acetophenone 4-nitrophenylhydrazone inhibits Hepatitis B virus replication by modulating capsid assembly","volume":"306","author":"Yamasaki","year":"2021","journal-title":"Virus Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.1513803112","article-title":"High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein","volume":"112","author":"Klumpp","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1128\/AAC.46.9.3057-3060.2002","article-title":"Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and Lamivudine-resistant strains of hepatitis B virus in vitro","volume":"46","author":"Edwards","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kim, H., Ko, C., Lee, J.-Y., and Kim, M. (2021). Current progress in the development of hepatitis B virus capsid assembly modulators: Chemical structure, mode-of-action and efficacy. Molecules, 26.","DOI":"10.3390\/molecules26247420"},{"key":"ref_142","first-page":"167","article-title":"Hepatitis C virus RNA replication","volume":"369","author":"Lohmann","year":"2013","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4254\/wjh.v10.i2.186","article-title":"Hepatitis C virus: Morphogenesis, infection and therapy","volume":"10","author":"Morozov","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3748\/wjg.v27.i12.1117","article-title":"Cascade of care for children and adolescents with chronic hepatitis C","volume":"27","author":"Rogers","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"892","DOI":"10.7150\/ijms.43079","article-title":"Direct-acting antiviral in the treatment of chronic hepatitis C: Bonuses and challenges","volume":"17","author":"Zeng","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nyas.12832","article-title":"Development of sofosbuvir for the treatment of hepatitis C virus infection","volume":"1358","author":"Lawitz","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1074\/jbc.M111392200","article-title":"Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity","volume":"277","author":"Shirota","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/emmm.201303131","article-title":"Emerging therapies for the treatment of hepatitis C","volume":"6","author":"Lange","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"8607","DOI":"10.1093\/nar\/gks623","article-title":"Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays","volume":"40","author":"Mukherjee","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.bbalip.2018.06.002","article-title":"Complex lipid metabolic remodeling is required for efficient hepatitis C virus replication","volume":"1863","author":"Hofmann","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2017.10.016","article-title":"Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles","volume":"148","author":"Hu","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2005-864785","article-title":"Hepatitis C virus particles and lipoprotein metabolism","volume":"25","author":"Perlemuter","year":"2005","journal-title":"Semin. Liver Dis."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1038\/s41598-017-02648-6","article-title":"Glycogen synthase kinase 3\u03b2 inhibitors prevent hepatitis C virus release\/assembly through perturbation of lipid metabolism","volume":"7","author":"Sarhan","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijantimicag.2016.01.012","article-title":"Allosteric heat shock protein 70 inhibitors block hepatitis C virus assembly","volume":"47","author":"Khachatoorian","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.22852","article-title":"The heat shock cognate protein 70 is associated with hepatitis C virus particles and modulates virus infectivity","volume":"49","author":"Parent","year":"2009","journal-title":"Hepatology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3389\/fmicb.2020.01577","article-title":"Mechanism and complex roles of HSC70 in viral infections","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/7355_2018_47","article-title":"The discovery and development of daclatasvir: An inhibitor of the hepatitis C virus NS5A replication complex","volume":"32","author":"Meanwell","year":"2018","journal-title":"HCV J. Discov. Cure"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/j.gastro.2016.11.047","article-title":"Daclatasvir prevents hepatitis C virus infectivity by blocking transfer of the viral genome to assembly sites","volume":"152","author":"Boson","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.antiviral.2015.10.018","article-title":"Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay","volume":"124","author":"Hu","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3851\/IMP3303","article-title":"Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle","volume":"24","author":"Park","year":"2019","journal-title":"Antivir. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Neveu, G., Barouch-Bentov, R., Ziv-Av, A., Gerber, D., Jacob, Y., and Einav, S. (2012). Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002845"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/s41564-020-0781-2","article-title":"Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion","volume":"5","author":"Ma","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"282ra49","DOI":"10.1126\/scitranslmed.3010286","article-title":"Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection","volume":"7","author":"He","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/infdis\/jiy039","article-title":"Preclinical pharmacological development of chlorcyclizine derivatives for the treatment of hepatitis C virus infection","volume":"217","author":"Rolt","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"9431","DOI":"10.1021\/acs.jmedchem.1c00696","article-title":"Discovery and optimization of a 4-aminopiperidine scaffold for inhibition of hepatitis C virus assembly","volume":"64","author":"Rolt","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1099\/vir.0.008565-0","article-title":"Peptide inhibitors of hepatitis C virus core oligomerization and virus production","volume":"90","author":"Kota","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1089\/adt.2009.0217","article-title":"A time-resolved fluorescence\u2013resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization","volume":"8","author":"Kota","year":"2009","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.bmcl.2011.03.014","article-title":"Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents","volume":"21","author":"Ni","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Kota, S., Takahashi, V., Ni, F., Snyder, J.K., and Strosberg, A.D. (2012). Direct binding of a hepatitis C virus inhibitor to the viral capsid protein. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032207"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"100216","DOI":"10.1016\/j.onehlt.2021.100216","article-title":"Animals as potential reservoirs for dengue transmission: A systematic review","volume":"12","author":"Gwee","year":"2021","journal-title":"One Health"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1248\/cpb.c17-00794","article-title":"Dengue virus and its inhibitors: A brief review","volume":"66","author":"Tian","year":"2018","journal-title":"Chem. Pharm. Bull"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/AAC.01429-12","article-title":"A novel inhibitor of dengue virus replication that targets the capsid protein","volume":"57","author":"Byrd","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"11540","DOI":"10.1128\/JVI.01745-14","article-title":"Characterization of the mode of action of a potent dengue virus capsid inhibitor","volume":"88","author":"Scaturro","year":"2014","journal-title":"J. Virol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/adt.2010.0321","article-title":"High-content assay to identify inhibitors of dengue virus infection","volume":"8","author":"Shum","year":"2010","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2018.04.019","article-title":"Characterization and structure-activity relationship analysis of a class of antiviral compounds that directly bind dengue virus capsid protein and are incorporated into virions","volume":"155","author":"Smith","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1099\/vir.0.023325-0","article-title":"Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase","volume":"92","author":"Mousseau","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"166725","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"Arya","year":"2021","journal-title":"J. Mol. Biol."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Mahtarin, R., Islam, S., Islam, M.J., Ullah, M.O., Ali, M.A., and Halim, M.A. (2020). Structure and dynamics of membrane protein in SARS-CoV-2. J. Biomol. Struct. Dyn., 1\u201314.","DOI":"10.1080\/07391102.2020.1861983"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e105938","DOI":"10.15252\/embj.2020105938","article-title":"Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design","volume":"39","author":"Peng","year":"2020","journal-title":"EMBO J."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2020.09.131","article-title":"High-resolution structure and biophysical characterization of the nucleocapsid phosphoprotein dimerization domain from the Covid-19 severe acute respiratory syndrome coronavirus 2","volume":"538","author":"Zinzula","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12104-020-09995-y","article-title":"(1)H, (13)C, and (15)N backbone chemical shift assignments of the C-terminal dimerization domain of SARS-CoV-2 nucleocapsid protein","volume":"15","author":"Korn","year":"2021","journal-title":"Biomol. NMR Assign"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/s41594-020-00536-8","article-title":"Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers","volume":"27","author":"Mandala","year":"2020","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"104451","DOI":"10.1016\/j.meegid.2020.104451","article-title":"Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches","volume":"84","author":"Bhowmik","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: The rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Ahamad, S., Gupta, D., and Kumar, V. (2020). Targeting SARS-CoV-2 nucleocapsid oligomerization: Insights from molecular docking and molecular dynamics simulations. J. Biomol. Struct. Dyn., 1\u201314.","DOI":"10.1080\/07391102.2020.1839563"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Patocka, J., Kuca, K., Oleksak, P., Nepovimova, E., Valis, M., Novotny, M., and Klimova, B. (2021). Rapamycin: Drug repurposing in SARS-CoV-2 infection. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030217"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"109282","DOI":"10.1016\/j.cbi.2020.109282","article-title":"Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19","volume":"331","author":"Husain","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.xphs.2021.03.004","article-title":"Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2","volume":"110","author":"Peele","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"e06387","DOI":"10.1016\/j.heliyon.2021.e06387","article-title":"The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing","volume":"7","author":"Hu","year":"2021","journal-title":"Heliyon"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1021\/acscentsci.0c01186","article-title":"Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir","volume":"7","author":"Lo","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e02680-20","DOI":"10.1128\/AAC.02680-20","article-title":"Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in vitro","volume":"65","author":"Gammeltoft","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acsptsci.0c00108","article-title":"Identification of SARS-CoV-2 3CL protease inhibitors by a quantitative high-throughput screening","volume":"3","author":"Zhu","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000149376","article-title":"Portraits of viruses: The picornaviruses","volume":"20","author":"Melnick","year":"1983","journal-title":"Intervirology"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12929-021-00708-8","article-title":"Antivirals blocking entry of enteroviruses and therapeutic potential","volume":"28","author":"Anasir","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0042-6822(87)90075-4","article-title":"Inhibition of poliovirus uncoating by disoxaril (WIN 51711)","volume":"160","author":"Zeichhardt","year":"1987","journal-title":"Virology"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/infdis\/159.5.866","article-title":"Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril","volume":"159","author":"Jubelt","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.41.6.1220","article-title":"SCH 48973: A potent, broad-spectrum, antienterovirus compound","volume":"41","author":"Buontempo","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.00671-09","article-title":"In vitro antiviral activity of V-073 against polioviruses","volume":"53","author":"Oberste","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0966-842X(02)02383-1","article-title":"Picornavirus\u2013receptor interactions","volume":"10","author":"Rossmann","year":"2002","journal-title":"Trends Microbiol"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1021\/jm00150a025","article-title":"[[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating","volume":"28","author":"Diana","year":"1985","journal-title":"J. Med. Chem."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2017.03.009","article-title":"Direct-acting antivirals and host-targeting strategies to combat enterovirus infections","volume":"24","author":"Bauer","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/jm00216a003","article-title":"Antiviral activity of some beta-diketones. 1. Aryl alkyl diketones. In vitro activity against both RNA and DNA viruses","volume":"20","author":"Diana","year":"1977","journal-title":"J. Med. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/jm00216a004","article-title":"Antiviral activity of some beta-diketones. 2. Aryloxy alkyl diketones. In vitro activity against both RNA and DNA viruses","volume":"20","author":"Diana","year":"1977","journal-title":"J. Med. Chem."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/jm00207a010","article-title":"Antiviral activity of some beta-diketones. 4. Benzyl diketones. In vitro activity against both RNA and DNA viruses","volume":"21","author":"Diana","year":"1978","journal-title":"J. Med. Chem."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/jm00205a019","article-title":"Antiviral activity of some beta-diketones. 3. Aryl bis(beta-diketones). Antiherpetic activity","volume":"21","author":"Diana","year":"1978","journal-title":"J. Med. Chem."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ejmech.2019.06.008","article-title":"Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses","volume":"178","author":"Egorova","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0042-6822(79)90342-8","article-title":"Inhibition of uncoating of poliovirus by arildone, a new antiviral drug","volume":"97","author":"McSharry","year":"1979","journal-title":"Virology"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1128\/AAC.27.6.883","article-title":"In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug","volume":"27","author":"Otto","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jac\/16.3.284","article-title":"WIN 51711, a new systematically active broad-spectrum antipicornavirus agent","volume":"16","author":"McKinlay","year":"1985","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1021\/jm00122a027","article-title":"Synthesis and structure-activity studies of some disubstituted phenylisoxazoles against human picornavirus","volume":"32","author":"Diana","year":"1989","journal-title":"J. Med. Chem."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1126\/science.3018924","article-title":"The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating","volume":"233","author":"Smith","year":"1986","journal-title":"Science"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/AAC.00227-06","article-title":"Enteroviral meningitis: Natural history and outcome of pleconaril therapy","volume":"50","author":"Desmond","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1086\/375069","article-title":"Pleconaril respiratory infection study group, Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials","volume":"36","author":"Hayden","year":"2003","journal-title":"Clin. Infect Dis."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/jm010536a","article-title":"Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: A novel class of potent and selective human enterovirus 71 inhibitors","volume":"45","author":"Shia","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1021\/jm050033v","article-title":"Design, synthesis, and antipicornavirus activity of 1-[5-(4-Arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives","volume":"48","author":"Chang","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/jm00167a006","article-title":"A model for compounds active against human rhinovirus-14 based on X-ray crystallography data","volume":"33","author":"Diana","year":"1990","journal-title":"J. Med. Chem."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0166-3542(93)90064-P","article-title":"SCH 38057: A picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating","volume":"21","author":"Rozhon","year":"1993","journal-title":"Antivir. Res."},{"key":"ref_220","first-page":"335","article-title":"Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model","volume":"215","author":"Collett","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/095632020001100402","article-title":"Antiviral therapy for enteroviruses and rhinoviruses","volume":"11","author":"Rotbart","year":"2000","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1128\/AAC.39.2.290","article-title":"Intranasal pirodavir (R77,975) treatment of rhinovirus colds","volume":"39","author":"Hayden","year":"1995","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.12688\/f1000research.11978.1","article-title":"Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma\/COPD pathogenesis","volume":"6","author":"Mirabelli","year":"2017","journal-title":"F1000Research"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/ml2002955","article-title":"An orally available 3-ethoxybenzisoxazole capsid binder with clinical activity against human rhinovirus","volume":"3","author":"Feil","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF01310997","article-title":"In vitro activity of R 61837, a new antirhinovirus compound","volume":"101","author":"Andries","year":"1988","journal-title":"Arch. Virol."},{"key":"ref_226","unstructured":"(2021, December 20). Aviragen Antiviral Drug Vapendavir Fails Phase IIb Study in Asthma Patients. Available online: https:\/\/www.genengnews.com\/topics\/drug-discovery\/aviragen-antiviral-drug-vapendavir-fails-phase-iib-study-in-asthma-patients\/."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1086\/318452","article-title":"Treatment of Potentially Life-Threatening Enterovirus Infections with Pleconaril","volume":"32","author":"Rotbart","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00508-017-1289-5","article-title":"Chronic meningoencephalitis caused by Echo virus 6 in a patient with common variable immunodeficiency","volume":"130","author":"Rkman","year":"2018","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.1222379110","article-title":"Structure of human enterovirus 71 in complex with a capsid-binding inhibitor","volume":"110","author":"Plevka","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nsmb.2769","article-title":"More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules","volume":"21","author":"Wang","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"19109","DOI":"10.1073\/pnas.1904732116","article-title":"Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site","volume":"116","author":"Wald","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1128\/AAC.48.9.3523-3529.2004","article-title":"Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone","volume":"48","author":"Shih","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"9719","DOI":"10.1038\/s41598-021-89271-8","article-title":"Novel capsid binder and PI4KIIIbeta inhibitors for EV-A71 replication inhibition","volume":"11","author":"Tan","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1021\/acs.jmedchem.7b00175","article-title":"A novel series of highly potent small molecule inhibitors of rhinovirus replication","volume":"60","author":"Kim","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"11163","DOI":"10.1128\/JVI.00640-12","article-title":"Symmetry-related clustering of positive charges is a common mechanism for heparan sulfate binding in enteroviruses","volume":"86","author":"Kaloudas","year":"2012","journal-title":"J. Virol."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Nishimura, Y., Lee, H., Hafenstein, S., Kataoka, C., Wakita, T., Bergelson, J.M., and Shimizu, H. (2013). Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003511"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"42902","DOI":"10.1038\/srep42902","article-title":"Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A","volume":"7","author":"Ren","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Nishimura, Y., McLaughlin, N.P., Pan, J., Goldstein, S., Hafenstein, S., Shimizu, H., Winkler, J.D., and Bergelson, J.M. (2015). The suramin derivative NF449 interacts with the 5-fold vertex of the enterovirus A71 capsid to prevent virus attachment to PSGL-1 and heparan sulfate. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005184"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1128\/AAC.00626-16","article-title":"Optimization of a class of tryptophan dendrimers that inhibit HIV replication leads to a selective, specific, and low-nanomolar inhibitor of clinical isolates of enterovirus A71","volume":"60","author":"Sun","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virusres.2012.06.025","article-title":"In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71","volume":"169","author":"Pourianfar","year":"2012","journal-title":"Virus Res."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1021\/acsinfecdis.9b00070","article-title":"Efficient blocking of enterovirus 71 infection by heparan sulfate analogues acting as decoy receptors","volume":"5","author":"Earley","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"e00061-19","DOI":"10.1128\/JVI.00061-19","article-title":"In vitro and in vivo inhibition of the infectivity of human enterovirus 71 by a sulfonated food azo dye, brilliant black BN","volume":"93","author":"Meng","year":"2019","journal-title":"J. Virol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/22221751.2020.1767512","article-title":"Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors","volume":"9","author":"Hsieh","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2017.10.004","article-title":"New class of early-stage enterovirus inhibitors with a novel mechanism of action","volume":"147","author":"Ma","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Abdelnabi, R., Geraets, J.A., Ma, Y., Mirabelli, C., Flatt, J.W., Domanska, A., Delang, L., Jochmans, D., Kumar, T.A., and Jayaprakash, V. (2019). A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. PLoS Biol., 17.","DOI":"10.1371\/journal.pbio.3000281"},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Bostina, M. (2019). Monoclonal antibodies point to Achilles\u2019 heel in picornavirus capsid. PLoS Biol., 17.","DOI":"10.1371\/journal.pbio.3000232"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.antiviral.2015.10.006","article-title":"Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16","volume":"124","author":"Kelly","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dki263","article-title":"Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: Antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment","volume":"56","author":"Schmidtke","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1128\/AAC.33.12.2069","article-title":"In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug","volume":"33","author":"Woods","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"105177","DOI":"10.1016\/j.antiviral.2021.105177","article-title":"Comparative analysis of the molecular mechanism of resistance to vapendavir across a panel of picornavirus species","volume":"195","author":"Lanko","year":"2021","journal-title":"Antiviral. Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/2\/174\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:03:15Z","timestamp":1760133795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/2\/174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":250,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["v14020174"],"URL":"https:\/\/doi.org\/10.3390\/v14020174","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}